Press Release FeedGet the RSS feed
Menu

Business Wire

AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership

Business Wire

  • Galderma will present eight posters spanning its full Injectable Aesthetics portfolio at AMWC Dubai 2026, highlighting the complementary benefits of Sculptra® and Restylane®, and pooled phase III study data for Relfydess® (relabotulinumtoxinA)1-8

  • With 30 years of innovation, Restylane continues to evolve through the development of new technologies and expanded clinical indications, with data to be presented from four studies across the chin, jawline, temples, and lower face

  • Several Meet-the-Expert sessions and a symposium on the AART™ of Body, which highlights new expanded indications for Sculptra in the gluteal area, posterior thighs, and décolletage, follows Sculptra's recent approval for use on the body in the United Arab Emirates (UAE)9

ZUG, Switzerland, October 21, 2026--Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taking place in Dubai, United Arab Emirates (UAE), from October 21-23, 2026. The company will present eight scientific abstracts, alongside a symposium and six Meet-the-Expert sessions, all highlighting the expanding benefits of Relfydess, Sculptra, and the Restylane range.1-8 Together, the data demonstrate Galderma's commitment to meeting the evolving needs of patients and healthcare professionals through innovation that addresses growing needs, from menopause-related skin changes and regenerative aesthetic solutions, to body indications.

Data across face and body indications showcase the power of Sculptra and Restylane
Data on Sculptra, the first proven regenerative biostimulator, will be shared at AMWC Dubai, following its approval in the UAE expanding its current clinical application for the face to include key body areas: the gluteal area, posterior thighs and décolletage.9 Guidance from an international consensus panel of 11 experts will be presented, outlining evidence-based recommendations on appropriate combination strategies across approved body indications.1 The recommendations highlight the complementary benefits of Sculptra and Restylane SkinboostersTM in the posterior thighs, and gluteal area, for comprehensive body rejuvenation.1

Data from Restylane ShaypeTM – the first-and-only hyaluronic acid (HA) shaper developed with novel NASHA-HD™ technology as well as expanded indications for Restylane LyftTM and Restylane VolymeTM* are being presented with clinical evidence in the chin, jawline, temples, and lower face.2 Across four studies, Restylane delivered well-tolerated, effective, and long-lasting aesthetic improvements in multiple facial regions, consistently achieving high responder rates and high subject satisfaction.2

  1. AIBeluuga AI, Inc.beluuga.ai Launches English-Language Equity Research, Targets 100% Coverage of Japanese Small- and Mid-Cap Stocks Within MonthsBuilt on proprietary data infrastructure, Beluuga Research launches with 20 companies to close Japan's research gap. TOKYO, October 21, 2026--Beluuga AI, Inc., developer of the beluuga.ai platform, today launched Beluuga Research, an English-language equity research service. It covers 20 Japanese companies now and plans 100% small- and mid-cap coverage within months. Japan has nearly 3,900 listed
  2. AIAI Emerges as CEOs' Most Critical Challenge, Egon Zehnder Study FindsThird annual edition of The CEO Response finds leaders prioritizing AI and business alliances as demands on CEO leadership grow ZURICH, October 21, 2026--Artificial intelligence has emerged as the most critical challenge facing CEOs worldwide, ahead of geopolitical instability and economic uncertainty,
  3. FinanceInnate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare ConferenceMARSEILLE, France, October 21, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (" Innate " or the " Company "), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its executive team will participate in the following investor conferences: Stifel Healthcare Conference Dates: November 10–12, 2026 Location:
  4. FinanceF5F5 and Telenor Partner to Build the AI Service Plane for Sovereign AI on NVIDIA-powered AI Factory InfrastructureCompanies: F5, Inc.NvidiaF5 BIG-IP Next for Kubernetes on NVIDIA BlueField DPU provides a Kubernetes-native control point for AI traffic, tenant isolation, telemetry, and policy SEATTLE, October 21, 2026--F5 (NASDAQ: FFIV), the global leader in delivering and securing every app and API, today announced that Telenor AI Factory
  5. HealthcareDepartment of Health – Abu Dhabi and ŌURA Launch Research Partnership to Study Early Warning Signs of Premature BirthProject CRADLE is a first-of-its-kind 24-month pilot study that will examine whether continuous wearable data can help predict spontaneous premature birth The study will lay the groundwork for predictive models that health systems could use to improve outcomes for mothers and babies ABU DHABI, United Arab Emirates, Octobe
  6. EnergyWoodside Energy GroupWoodside Energy Third Quarter Report for Period Ended 30 September 2026Strong performance from improved production and pricing Performance highlights Achieved $84/boe realised LNG price during Q3 2026, an increase of 27% compared to Q2 2026 reflecting price lags from Q2 2026, realised values from LNG portfolio optimisation undertaken in Q2 2026 and stronger gas hub market pricing. Delivered